Although Merck & Co. lost its patent battle with Mylan Pharmaceuticals over alleged infringement of patents for a drug to treat Parkinson’s disease, a federal judge has refused to award Mylan $1.5 million in attorney fees.

“Merck’s infringement claim, albeit erroneous, was not baseless,” U.S. District Judge Eduardo C. Robreno wrote. “Its course of conduct in pursuing the claim was neither vexatious, unusual nor disproportionate to the rather high stakes involved.”

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]